Trial Profile
Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Dexamethasone; Fosaprepitant; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms FOND-O
- 23 Mar 2018 Status changed from active, no longer recruiting to completed.
- 03 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.